董事长专访 | 麦澜德杨瑞嘉：按下脑机接口产业布局“快进键”

Core Viewpoint - 麦澜德 is a high-tech enterprise focusing on comprehensive physical intervention solutions for women's entire life cycle, recently highlighting its new strategic direction and advantages in the brain-computer interface (BCI) industry at the Jiangsu Province BCI Industry Alliance Conference [1][4] Company Strategy and Development - 麦澜德 has been involved in the BCI industry since 2019 and accelerated its development by joining the Jiangsu Province BCI Industry Alliance, which acts as a "fast forward" for the company's growth in this sector [5] - The company is currently developing a "multi-modal emotional interaction diagnostic and therapeutic device," which integrates various sensors to capture multiple parameters such as facial expressions and brain waves, aimed at assessing and rehabilitating conditions like Alzheimer's and depression [5][6] Product Development and Innovation - 麦澜德 has clinical applications of BCI technology in rehabilitation and has received positive feedback. The company is leading several national key research projects in collaboration with top institutions [6] - The company aims to upgrade all its medical products using BCI technology, focusing on personalized and precise closed-loop assessment and treatment, with plans to develop algorithms and equipment for cognitive and emotional function disorders [7] Market Position and Financial Performance - 麦澜德 has established a strong market presence in the pelvic floor and obstetrics rehabilitation sector, achieving a net profit exceeding 1 billion yuan for the first time in 2019 and becoming the first national specialized "little giant" enterprise in this field by 2020 [9][10] - In the first half of 2025, 麦澜德 reported revenue of 241 million yuan, a year-on-year increase of 5.62%, and a net profit of 60.72 million yuan, a decrease of 8.08% [11] Industry Outlook - The medical device industry in China is experiencing a "golden development period," with the overall industry revenue reaching 1.31 trillion yuan in 2023 and a compound annual growth rate of 10% from 2014 to 2023 [12] - 麦澜德's products are widely used in 26 countries and regions, with annual screening numbers exceeding 1.5 million and treatment numbers over 600,000 [12] Future Plans - 麦澜德 is focusing on expanding its business in reproductive rehabilitation and anti-aging, employing a dual strategy of internal growth and external acquisitions to enhance its competitive edge [13]